Neurim Loses European Patent For Insomnia Drug
A European appeals panel has refused to rekindle Neurim's insomnia drug patent, ruling in a decision released Thursday that officials did not misstep by making passing comments on the patent's validity...To view the full article, register now.
Already a subscriber? Click here to view full article